Abstract 273P
Background
We compared the diagnostic performance of cognitive transrectal MRI-targeted biopsy (MRITB) between three anatomical zones of the prostate.
Methods
Of the 569 initial cases with suspected prostate cancer, those who received standard biopsy (14-region, 18-core biopsy: SB) between June 2019 and March 2023 were selected (SB 57 cases, SB+MRITB 509 cases). SB alone was performed in PI-RADS v2.1 ≦2, and MRITB was added in ≧3. In this study, we investigated whether zonal anatomy affects the diagnostic performance of MRITB retrospectively.
Results
In 569 cases, 394 cases (69.2%) were positive for cancer. Of 394 cancer cases, 25 (6.3%) were from SB alone and 369 (93.7%) from SB+MRITB. According to the Epstein criteria, 359 cases (91.1%) were clinically significant. In all cases, the diagnostic performance of MRITB was 80.1% for sensitivity, 20.5% for specificity, 71.4% for positive predictive value, 29.4% for negative predictive value, and 63.0% for accuracy. The true positive rates of cancer detection by MRITB in each zone were 22 cores (43.1%) in CZ, 125 cores (41.9%) in TZ, and 283 cores (64.6%) in PZ. CZ and TZ groups were significantly lower than the PZ group, respectively, and especially, midgland TZ was the highest false-positive rates compared to midgland-apex TZ (87.3% v.s.33.3%).
Conclusions
In the case of SB including apex anterior biopsy, MRITB alone missed clinically significant cancers in 65 cases (18.1%) in PI-RADS v2.1 ≥3, which was a higher rate than those reported by many previous reports. In contrast, MRITB showed a high false-positive rate especially in TZ, suggesting that the positive criteria and approach model for these lesions need to be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Toyama.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract